Vandetanib induces a marked anti-tumor effect and amelioration of ectopic Cushing’s syndrome in a medullary thyroid carcinoma patient
A 55-year-old woman diagnosed with sporadic MTC underwent total thyroidectomy 20 years ago. After the first surgery, elevated calcitonin levels in parallel with local disease persistence were noted and therefore she underwent repeated neck dissections. During follow-up, multiple foci of metastatic d...
Main Authors: | Hashem Bseiso, Naama Lev-Cohain, David J Gross, Simona Grozinsky-Glasberg |
---|---|
Format: | Article |
Language: | English |
Published: |
Bioscientifica
2016-10-01
|
Series: | Endocrinology, Diabetes & Metabolism Case Reports |
Online Access: | https://www.edmcasereports.com/articles/endocrinology-diabetes-and-metabolism-case-reports/10.1530/EDM-16-0082 |
Similar Items
-
Rapid response of hypercortisolism to vandetanib treatment in a patient with advanced medullary thyroid cancer and ectopic Cushing syndrome
by: Fabián Pitoia, et al. -
Metastatic medullary thyroid carcinoma presenting as ectopic Cushing’s syndrome
by: Hannah E Forde, et al.
Published: (2021-04-01) -
Vandetanib for the Treatment of Metastatic Medullary Thyroid Cancer
by: Nils Degrauwe, et al.
Published: (2012-01-01) -
Vandetanib for the Treatment of Metastatic Medullary Thyroid Cancer
by: Nils Degrauwe, et al.
Published: (2012-06-01) -
Role of vandetanib in the management of medullary thyroid cancer
by: Rondeau G, et al.
Published: (2012-03-01)